|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online October 8, 2008
doi: 10.1242/10.1242/jcs.029223
Commentary |
MRC Protein Phosphorylation Unit, Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
MRC Protein Phosphorylation Unit, Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
e-mail: c.j.z.richardson{at}dundee.ac.uk
e-mail: d.r.alessi{at}dundee.ac.uk
Accepted 19 August 2008
It has recently been shown that the WNK [with-no-K(Lys)] kinases (WNK1, WNK2, WNK3 and WNK4) have vital roles in the control of salt homeostasis and blood pressure. This Commentary focuses on recent findings that have uncovered the backbone of a novel signal-transduction network that is controlled by WNK kinases. Under hyperosmotic or hypotonic low-Cl– conditions, WNK isoforms are activated, and subsequently phosphorylate and activate the related protein kinases SPAK and OSR1. SPAK and OSR1 phosphorylate and activate ion co-transporters that include NCC, NKCC1 and NKCC2, which are targets for the commonly used blood-pressure-lowering thiazide-diuretic and loop-diuretic drugs. The finding that mutations in WNK1, WNK4, NCC and NKCC2 cause inherited blood-pressure syndromes in humans highlights the importance of these enzymes. We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption. We also discuss unresolved and controversial questions in this field of research.
Key words: Ion co-transporters, SPAK, OSR1, WNK, Protein kinases
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
A. Ohta, T. Rai, N. Yui, M. Chiga, S.-S. Yang, S.-H. Lin, E. Sohara, S. Sasaki, and S. Uchida Targeted disruption of the Wnk4 gene decreases phosphorylation of Na-Cl cotransporter, increases Na excretion and lowers blood pressure Hum. Mol. Genet., October 15, 2009; 18(20): 3978 - 3986. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gamba The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs Am J Physiol Renal Physiol, October 1, 2009; 297(4): F838 - F848. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vallon, J. Schroth, F. Lang, D. Kuhl, and S. Uchida Expression and phosphorylation of the Na+-Cl- cotransporter NCC in vivo is regulated by dietary salt, potassium, and SGK1 Am J Physiol Renal Physiol, September 1, 2009; 297(3): F704 - F712. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Mount Splicing a Kinase and the Regulation of Salt Transport J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1166 - 1168. [Full Text] [PDF] |
||||
![]() |
P. San-Cristobal, D. Pacheco-Alvarez, C. Richardson, A. M. Ring, N. Vazquez, F. H. Rafiqi, D. Chari, K. T. Kahle, Q. Leng, N. A. Bobadilla, et al. Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway PNAS, March 17, 2009; 106(11): 4384 - 4389. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, J. R. O'Connell, P. F. McArdle, J. B. Wade, S. E. Dorff, S. J. Shah, X. Shi, L. Pan, E. Rampersaud, H. Shen, et al. From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene PNAS, January 6, 2009; 106(1): 226 - 231. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Balda and K. Matter Tight junctions at a glance J. Cell Sci., November 15, 2008; 121(22): 3677 - 3682. [Full Text] [PDF] |
||||